🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  2. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  4. GENTAMICINE PANPHARMA 80 mg, solution injectable, Gentamicin Placebo, Metronidazole Biogaran 500 mg Placebo, Natriumchlorid-Lösung 0,9 % Deltamedica, Injektionslösung, METRONIDAZOLE BIOGARAN 500 mg, comprimé pelliculé

    Pari Pharma GmbH

    Acute mesenteric ischemia

    phase 3 small molecule active

    1 trial

  5. GLASSIA

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 3 mab completed

    1 trial

  6. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  7. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  8. GLPG1690

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    2 trials

  9. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  10. GLUCOTHERA PLUS

    Lacuna Pharma Pty Ltd

    End-stage Kidney Disease

    phase 3 small molecule active

    1 trial

  11. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  12. GS-100

    Grace Therapeutics

    NGLY1 Deficiency

    phase 3 gene therapy active

    1 trial

  13. GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  14. GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  15. GS-5245 tablets 175 mg, GS-5245 tablets 350 mg

    Gilead Sciences Pty Limited

    COVID-19

    phase 3 small molecule active

    1 trial

  16. GS1191-0445 injection

    Gritgen Therapeutics Co.,

    Hemophilia A

    phase 3 small molecule active

    1 trial

  17. GSK 2132231A

    GlaxoSmithKline

    Melanoma

    phase 3 small molecule terminated

    1 trial

  18. GSK1605786A

    GlaxoSmithKline

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

  19. GSK2118436

    GlaxoSmithKline

    Cancer

    phase 3 small molecule completed

    1 trial

  20. GSK2585823(CLDM 1%-BPO 3% gel)

    GlaxoSmithKline

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  21. GSK3196165 (Otilimab)

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 3 mab completed

    1 trial

  22. GTX-102

    Ultragenyx UK Limited

    Angelman Syndrome

    phase 3 small molecule active

    4 trials

  23. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  24. GTX-104

    Grace Therapeutics

    Aneurysmal Subarachnoid Hemorrhage (aSAH)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources